• Donatella Severini and Kwame Mboumi.
• a Heart Failure Ambulatory, Cardiology Unit , Hospital Città Di Castello , Città Di Castello , Italy.
• Curr Med Res Opin. 2019 May 1; 35 (sup3): 7-11.

AbstractSacubitril/valsartan was shown to be effective in improving the clinical outcome and reducing hospitalization rate and mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction (HFrEF). Here we report a case series of three patients with HFrEF associated with mitral insufficiency (case #1), dilated cardiomyopathy (case #2) and chronic ischaemia (case #3). The first case was a 49 year old male and the further two were 70 year old male patients. After previous ineffective treatment, the administration of sacubitril/valsartan led to a rapid and marked improvement of the clinical conditions in all three cases. Moreover, in two patients, angiotensin receptor-neprilysin inhibitor (ARNI) therapy avoided a surgical intervention for the insertion of an implantable cardioverter defibrillator. In the third patient, sacubitril/valsartan interrupted a long series of hospitalizations for acute HF. Based on our experience, we conclude that treatment with ARNI allows better treatment optimization with a positive impact on the control of HF and related comorbidities.

22 keywords...

hide…